<DOC>
	<DOCNO>NCT00005076</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness cetuximab irinotecan treating patient advance colorectal cancer respond previous treatment .</brief_summary>
	<brief_title>Cetuximab Irinotecan Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete partial response rate time progression patient refractory advance colorectal carcinoma treat cetuximab irinotecan . II . Determine safety toxicity profile regimen patient . III . Assess quality life patient treat regimen . IV . Determine tumor epidermal growth factor receptor level patient treat regimen . OUTLINE : This multicenter study . Patients stratify response irinotecan base chemotherapy regimen ( stable disease vs disease progression ) . Patients receive test dose cetuximab IV 10 minute day 1 . Patients experience grade 4 anaphylactic reaction receive load dose cetuximab IV 2 hour begin 30 minute completion test dose . Patients receive maintenance cetuximab IV 1 hour day 8 , 15 , 22 , 29 , 36 . Patients receive irinotecan IV 90 minute ( begin 1 hour completion cetuximab infusion ) regimen ( dosage frequency ) patient become refractory irinotecan therapy . Irinotecan administer high dose day 1 22 OR low dose day 1 , 8 , 15 , 22 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Patients unacceptable toxicity irinotecan may continue cetuximab maintenance therapy alone discretion protocol investigator sponsor . Quality life assess initiation study therapy , completion course , 4 week completion study . Patients follow 4 week . PROJECTED ACCRUAL : Approximately 110 patient ( 55 per stratum ) accrue study within 7 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove refractory advanced colorectal carcinoma Must 1 following : Stable disease receive minimum 12 week irinotecan Disease progression time receive irinotecan contain regimen No prior chemotherapy colorectal carcinoma interval irinotecan contain regimen study entry Bidimensionally measurable disease Index lesion must outside prior radiation port Epidermal growth factor receptor ( EGFr ) expression ( 1+ great ) must confirm prior study entry Patients tumor tissue available immunohistochemical assay EGFr test undergo biopsy accessible tumor No meningeal CNS involvement tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN ALT AST great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No clinically significant cardiac disease No serious arrhythmias No significant conduction abnormality Neurologic : No uncontrolled seizure disorder No active neurologic disease No grade 2 bad neuropathy Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 3 year except basal cell skin cancer preinvasive carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine monoclonal antibody therapy cetuximab Chemotherapy : See Disease Characteristics Recovered toxicities No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 month since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics At least 1 month since prior surgery except diagnostic biopsy Other : At least 1 month since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>